chronic myeloid leukaemia Archives -

Novartis has claimed FDA approval for one of its ‘wild card’ drugs – Scemblix – a first-in-class STAMP

Novartis’ ‘wild card’ drug Scemblix gets FDA nod for leukaemia

https://pharmaphorum.com/news/novartis-wild-card-drug-scemblix-gets-fda-nod-for-leukaemia/

A first-in-class STAMP inhibitor developed by Novartis – asciminib – has outperformed a current drug for chronic myeloid

Novartis eyes filings for leukaemia drug asciminib after phase 3 win

https://pharmaphorum.com/news/novartis-eyes-filings-for-leukaemia-drug-asciminib-after-phase-3-win/

US pharmacy chain CVS Specialty has made its two-way messaging app available to 80% of eligible patients on

CVS rolls out digital messaging for meds adherence after pilot

https://pharmaphorum.com/news/cvs-rolls-out-digital-messaging-for-meds-adherence-after-pilot/

Cancer Research UK granted £3.1m (nearly $4m) to a group of researchers at the University of Glasgow to

Cancer Research UK gives $4m funding to Glasgow Uni CML project

https://pharmaphorum.com/news/experimental-leukaemia-study-grant/

Bosulif is first drug to be funded following reassessment.

Pfizer leukaemia drug accepted by NICE

https://pharmaphorum.com/news/pfizer-leukaemia-drug-accepted-nice/

chronic myeloid leukaemia